How are people responding to Tecvayli treatment?
Tecvayli (teclistamab-cqyv) has shown promising results for people with relapsed or refractory multiple myeloma. Here's what the clinical trial data shows:
Response Rates
- About 73% of people had an overall response to treatment
- Approximately 32% achieved a complete Show Full Answer
How are people responding to Tecvayli treatment?
Tecvayli (teclistamab-cqyv) has shown promising results for people with relapsed or refractory multiple myeloma. Here's what the clinical trial data shows:
Response Rates:
- About 73% of people had an overall response to treatment
- Approximately 32% achieved a complete response, meaning all signs of cancer disappeared
- Most people began responding within a little over a month of starting treatment
Duration of Response:
- 85% of people who responded were still in response after 9 months of treatment
These results offer hope for people whose myeloma has returned or hasn't responded to other treatments. Tecvayli is a bispecific T-cell engager that works by helping your immune system target myeloma cells.
Like all treatments, Tecvayli can cause side effects. It's important to discuss potential reactions with your healthcare team and let them know about any uncomfortable or concerning symptoms during treatment.
If you're considering Tecvayli, talk with your oncologist about whether it might be a good fit based on your treatment history and overall health.
March 15
Join
Your Privacy Choices
